The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...
Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.
The US Food and Drug Administration (FDA) has accepted for priority review Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...
Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...
Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...
Treatment depends on how deep the melanoma is and whether it has spread. This is called the stage of the cancer. Treatment also depends on your general health and where the melanoma is on your body.
The best flea treatments for cats are veterinarian-approved, safe, and effective, and often control other parasites like ticks, worms, and lice. I made my recommendations for this guide after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results